Chang-hong Li1, Lin-lin Xu2, Jin-xia Zhao1, Lin Sun1, Zhong-qiang Yao1, Xiao-li Deng1, Rui Liu1, Lin Yang1, Rui Xing1, Xiang-yuan Liu3. 1. Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, People's Republic of China. 2. Department of Clinical Nutrition, First Hospital of Tsinghua Univiersity, Beijing, 100016, People's Republic of China. 3. Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, People's Republic of China. liu-xiangyuan@263.net.
Abstract
OBJECTIVE: To explore the influence of chemokine, CXCL16, on the expression of the receptor activator nuclear factor κB ligand (RANKL) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS). METHODS: The expression of CXCL16/CXCR6 and RANKL in RA or osteoarthritis (OA) patient synovia was examined by Western blot and immunohistochemistry. The serum concentration of CXCL16 and RANKL was measured by enzyme-linked immunosorbent assay (ELISA). RA-FLS were treated with recombinant CXCL16, and RANKL mRNA and protein were measured using PCR, Western blot and ELISA. RESULTS: The synovial expression of CXCL16, CXCR6, and RANKL was higher in RA patients than in patients with OA. The serum CXCL16 and RANKL levels were higher in RA patients compared with OA patients and healthy controls. CXCL16 correlated with erythrocyte sedimentation rate, C reactive protein, disease activity, serum rheumatoid factor, and RANKL. RA-FLS treated with CXCL16 showed markedly increased expression of RANKL. When STAT3 or p38 activation was blocked by an inhibitor, CXCL16 failed to upregulate RANKL expression. In contrast, inhibiting the Akt or Erk pathway did not achieve the same effect. CONCLUSIONS: CXCL16 upregulates RANKL expression in RA-FLS and these effects are mainly mediated by the JAK2/STAT3 and p38/MAPK signaling pathways.
OBJECTIVE: To explore the influence of chemokine, CXCL16, on the expression of the receptor activator nuclear factor κB ligand (RANKL) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS). METHODS: The expression of CXCL16/CXCR6 and RANKL in RA or osteoarthritis (OA) patient synovia was examined by Western blot and immunohistochemistry. The serum concentration of CXCL16 and RANKL was measured by enzyme-linked immunosorbent assay (ELISA). RA-FLS were treated with recombinant CXCL16, and RANKL mRNA and protein were measured using PCR, Western blot and ELISA. RESULTS: The synovial expression of CXCL16, CXCR6, and RANKL was higher in RApatients than in patients with OA. The serum CXCL16 and RANKL levels were higher in RApatients compared with OA patients and healthy controls. CXCL16 correlated with erythrocyte sedimentation rate, C reactive protein, disease activity, serum rheumatoid factor, and RANKL. RA-FLS treated with CXCL16 showed markedly increased expression of RANKL. When STAT3 or p38 activation was blocked by an inhibitor, CXCL16 failed to upregulate RANKL expression. In contrast, inhibiting the Akt or Erk pathway did not achieve the same effect. CONCLUSIONS:CXCL16 upregulates RANKL expression in RA-FLS and these effects are mainly mediated by the JAK2/STAT3 and p38/MAPK signaling pathways.
Authors: Peter J Gough; Kyle J Garton; Paul T Wille; Marcin Rychlewski; Peter J Dempsey; Elaine W Raines Journal: J Immunol Date: 2004-03-15 Impact factor: 5.422
Authors: Esmeralda T H Molenaar; Alexandre E Voskuyl; Huib J Dinant; P Dick Bezemer; Maarten Boers; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-01
Authors: Soeren Abel; Christian Hundhausen; Rolf Mentlein; Alexander Schulte; Theo A Berkhout; Neil Broadway; Dieter Hartmann; Radek Sedlacek; Sebastian Dietrich; Barbara Muetze; Bjoern Schuster; Karl-Josef Kallen; Paul Saftig; Stefan Rose-John; Andreas Ludwig Journal: J Immunol Date: 2004-05-15 Impact factor: 5.422
Authors: Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda Journal: Am J Respir Crit Care Med Date: 2018-05-01 Impact factor: 21.405
Authors: Fernanda Rocha Chaves Moreira; Tiago Almeida de Oliveira; Nádia Eliza Ramos; Maria Augusta Duarte Abreu; Ana Cristina Simões E Silva Journal: Mol Biol Rep Date: 2021-08-20 Impact factor: 2.316
Authors: Krista Kuuliala; Antti Kuuliala; Riitta Koivuniemi; Hannu Kautiainen; Heikki Repo; Marjatta Leirisalo-Repo Journal: Arthritis Res Ther Date: 2017-04-11 Impact factor: 5.156